504 related articles for article (PubMed ID: 27663742)
1. Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice.
Sawicka K; Pyronneau A; Chao M; Bennett MV; Zukin RS
Proc Natl Acad Sci U S A; 2016 Oct; 113(41):E6290-E6297. PubMed ID: 27663742
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of mTOR signaling in fragile X syndrome.
Sharma A; Hoeffer CA; Takayasu Y; Miyawaki T; McBride SM; Klann E; Zukin RS
J Neurosci; 2010 Jan; 30(2):694-702. PubMed ID: 20071534
[TBL] [Abstract][Full Text] [Related]
3. STEP inhibition reverses behavioral, electrophysiologic, and synaptic abnormalities in Fmr1 KO mice.
Chatterjee M; Kurup PK; Lundbye CJ; Hugger Toft AK; Kwon J; Benedict J; Kamceva M; Banke TG; Lombroso PJ
Neuropharmacology; 2018 Jan; 128():43-53. PubMed ID: 28943283
[TBL] [Abstract][Full Text] [Related]
4. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice.
Bhattacharya A; Kaphzan H; Alvarez-Dieppa AC; Murphy JP; Pierre P; Klann E
Neuron; 2012 Oct; 76(2):325-37. PubMed ID: 23083736
[TBL] [Abstract][Full Text] [Related]
5. S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade.
Narayanan U; Nalavadi V; Nakamoto M; Thomas G; Ceman S; Bassell GJ; Warren ST
J Biol Chem; 2008 Jul; 283(27):18478-82. PubMed ID: 18474609
[TBL] [Abstract][Full Text] [Related]
6. R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.
Qin M; Huang T; Kader M; Krych L; Xia Z; Burlin T; Zeidler Z; Zhao T; Smith CB
Int J Neuropsychopharmacol; 2015 Mar; 18(9):. PubMed ID: 25820841
[TBL] [Abstract][Full Text] [Related]
7. Recruitment of the extracellular signal-regulated kinase/ribosomal S6 kinase signaling pathway to the NFATc4 transcription activation complex.
Yang TT; Xiong Q; Graef IA; Crabtree GR; Chow CW
Mol Cell Biol; 2005 Feb; 25(3):907-20. PubMed ID: 15657420
[TBL] [Abstract][Full Text] [Related]
8. Analysis of FMR1 deletion in a subpopulation of post-mitotic neurons in mouse cortex and hippocampus.
Amiri A; Sanchez-Ortiz E; Cho W; Birnbaum SG; Xu J; McKay RM; Parada LF
Autism Res; 2014 Feb; 7(1):60-71. PubMed ID: 24408886
[TBL] [Abstract][Full Text] [Related]
9. Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome.
Liu ZH; Huang T; Smith CB
Neurobiol Dis; 2012 Mar; 45(3):1145-52. PubMed ID: 22227453
[TBL] [Abstract][Full Text] [Related]
10. Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.
Kumari D; Bhattacharya A; Nadel J; Moulton K; Zeak NM; Glicksman A; Dobkin C; Brick DJ; Schwartz PH; Smith CB; Klann E; Usdin K
Hum Mutat; 2014 Dec; 35(12):1485-94. PubMed ID: 25224527
[TBL] [Abstract][Full Text] [Related]
11. Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome.
Wang X; Snape M; Klann E; Stone JG; Singh A; Petersen RB; Castellani RJ; Casadesus G; Smith MA; Zhu X
J Neurochem; 2012 May; 121(4):672-9. PubMed ID: 22393900
[TBL] [Abstract][Full Text] [Related]
12. Identification of FMRP target mRNAs in the developmental brain: FMRP might coordinate Ras/MAPK, Wnt/β-catenin, and mTOR signaling during corticogenesis.
Casingal CR; Kikkawa T; Inada H; Sasaki Y; Osumi N
Mol Brain; 2020 Dec; 13(1):167. PubMed ID: 33323119
[TBL] [Abstract][Full Text] [Related]
13. p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling.
Abe Y; Yoon SO; Kubota K; Mendoza MC; Gygi SP; Blenis J
J Biol Chem; 2009 May; 284(22):14939-48. PubMed ID: 19332537
[TBL] [Abstract][Full Text] [Related]
14. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.
Hoeffer CA; Sanchez E; Hagerman RJ; Mu Y; Nguyen DV; Wong H; Whelan AM; Zukin RS; Klann E; Tassone F
Genes Brain Behav; 2012 Apr; 11(3):332-41. PubMed ID: 22268788
[TBL] [Abstract][Full Text] [Related]
15. Disruption of GpI mGluR-Dependent Cav2.3 Translation in a Mouse Model of Fragile X Syndrome.
Gray EE; Murphy JG; Liu Y; Trang I; Tabor GT; Lin L; Hoffman DA
J Neurosci; 2019 Sep; 39(38):7453-7464. PubMed ID: 31350260
[TBL] [Abstract][Full Text] [Related]
16. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation.
Roux PP; Shahbazian D; Vu H; Holz MK; Cohen MS; Taunton J; Sonenberg N; Blenis J
J Biol Chem; 2007 May; 282(19):14056-64. PubMed ID: 17360704
[TBL] [Abstract][Full Text] [Related]
17. Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome.
Kim SH; Markham JA; Weiler IJ; Greenough WT
Proc Natl Acad Sci U S A; 2008 Mar; 105(11):4429-34. PubMed ID: 18332424
[TBL] [Abstract][Full Text] [Related]
18. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
19. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
[TBL] [Abstract][Full Text] [Related]
20. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome.
Gross C; Nakamoto M; Yao X; Chan CB; Yim SY; Ye K; Warren ST; Bassell GJ
J Neurosci; 2010 Aug; 30(32):10624-38. PubMed ID: 20702695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
